| 查看: 794 | 回复: 5 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
zqxia2009铁杆木虫 (正式写手)
|
[求助]
最近在翻译吉非替尼的有关内容，有些地方遇到坎了，请求帮助
|
|
|
请帮忙翻译一下语句： 1、Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. 2、Hybrid physiologically based PK/PD models were developed for each tumor type, which consisted of a forcing function describing the plasma drug concentration profile, a tumor compartment depicting drug disposition in tumor, and a mechanistic target-response PD model characterizing pERK in the tumor. Gefitinib showed analogous PK properties in each tumor type yet different PD characteristics consistent with the EGFR status of the tumors. Using the PK/PD model for each tumor type, simulations were done to define multiple-dose regimens for gefitinib that yielded equivalent PD profiles of pERK in each tumor type. The novel concept of PK/PD equivalent dosing regimens could be applied in drug development and to delineate PG differences in drug activity. 3、this study was to evaluate if the hormonal therapy with BCLT can affect the EGFR-targeted therapy using primary cultures obtained from 22 human PCa tissues harvested after radical prostatectomy (RP) in patients who received (n=10) BCLT and those that did not (n=12) as neoadjuvant hormone therapy (NHT). We demonstrated that cultures derived from PCa tissues harvested after NHT presented significantly higher EGFR and Her2 levels compared to cultures derived from control patients. However, cultures derived from patients with NHT were less sensitive to gefitinib when compared to cultures derived from control patients. Conversely, BCLT effectiveness did not seem to be different in the two groups and was partially additive with gefitinib in the NHT group and additive/synergistic in the control group. Cultures (8/22) were negative for the expression of the PTEN gene and we observed no differences in the two groups. Thus the different IC50 values observed for gefitinib and the partial additivity in the combination treatment with gefitinib and BCLT is influenced by EGFR/Her2 ratio because it was shown that EGFR inhibition was lower when Her2 is overexpressed. Taken together, our results indicate that anti-EGFR targeted therapies and a possible combination therapy involving gefitinib and BCLT should be performed early in naive patients when Her2 is not overexpressed and before the anti-androgenic hormone therapy induces such an undesirable effect. 4、Cancer Chemother Pharmacol. 2012 Jan;69(1):273-80. Epub 2011 Oct 15. 5、Center for Applied Molecular Medicine, University of Southern California Westside Cancer Center, Beverly Hills, CA, USA. 6、PMID:22002543[PubMed - indexed for MEDLINE] |
回复此楼» 猜你喜欢
全日制（定向）博士
已经有5人回复
-
假如你的研究生提出不合理要求
已经有10人回复
-
萌生出自己或许不适合搞科研的想法，现在跑or等等看？
已经有4人回复
-
Materials Today Chemistry审稿周期
已经有4人回复
-
参与限项
已经有3人回复
-
实验室接单子
已经有4人回复
-
对氯苯硼酸纯化
已经有3人回复
-
求助:我三月中下旬出站，青基依托单位怎么办？
已经有12人回复
-
所感
已经有4人回复
-
要不要辞职读博？
已经有7人回复
球虎
木虫 (正式写手)
- 应助: 2 (幼儿园)
- 金币: 1800.5
- 散金: 40
- 红花: 4
- 帖子: 485
- 在线: 147.1小时
- 虫号: 1922071
- 注册: 2012-08-03
- 性别: GG
- 专业: 合成药物化学
4楼2013-05-03 11:47:56
2楼2013-05-03 10:10:09
球虎
木虫 (正式写手)
- 应助: 2 (幼儿园)
- 金币: 1800.5
- 散金: 40
- 红花: 4
- 帖子: 485
- 在线: 147.1小时
- 虫号: 1922071
- 注册: 2012-08-03
- 性别: GG
- 专业: 合成药物化学
|
1、Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. 关于吉非替尼的前临床药代动力学/药效动力学模型 和 针对含有野生/变种表皮生长因子受体的肿瘤的等效药物治疗模型的开发。 这句应该不完整吧，到这才有两个名词概念而已 顺便，如果你是在做毕设的本科生，建议你不要把毕业论文和毕业文献翻译太当儿戏 你丢上来的东西都是字面意思，你把不认识的词查清楚，不存在翻不出的问题。 又不是文学艺术类的文章，有复杂的修辞和语言活用，自己想破头也弄不明白。。。 |
3楼2013-05-03 11:47:19
求知者001
荣誉版主 (知名作家)
全球通，能否？！
- 外语EPI: 7
- 应助: 145 (高中生)
- 贵宾: 2.369
- 金币: 12125.8
- 散金: 4763
- 红花: 223
- 沙发: 13
- 帖子: 7305
- 在线: 859.2小时
- 虫号: 1129111
- 注册: 2010-10-22
- 性别: MM
- 专业: 环境污染化学
- 管辖: 外语学习
5楼2013-05-03 14:35:19